The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome

The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome - Japanese Committee of Clinical Guidelines for Myasthenia Gravis

The revised Japanese clinical guidelines for myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome (LEMS) were published in 2022. The notable points inthese guidelines (GLs) are as follows: (i) these are the first Japanese GLs to include adescription of LEMS; (ii) diagnostic criteria of MG are revised to lessen the incidenceof false negative patients; (iii) MG is divided into six clinical subtypes; (iv) a high-doseoral steroid regimen with escalation and de-escalation schedule is not recommendedby the GLs; (v) the GLs promote the early fast-acting treatment strategy initially pro-posed in the previous GLs; (vi) refractory MG is defined; (vii) the use of molecular tar-geted drugs is included; (viii) diagnostic criteria of LEMS are proposed; and(ix) treatment algorithms for both MG and LEMS are presented. These new GLs areexpected to improve the patients' quality of life and will serve to bridge the presentera with the molecular targeted treatment eras.


Read full Guideline